| New Defibrillator Avoids Wires in Heart Researchers developed a new type of implantable defibrillator that avoids the traditional technique of connecting directly to the heart with wires that are associated with complications. online.wsj.com |
FDA to Review Weight-Loss Drug The FDA will review Vivus's experimental weight-loss drug on Thursday. It could be the first new obesity treatment approved in the U.S. since 1999. online.wsj.com |
Genoptix Reports Operating Results for the Second Quarter 2010 (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, today reported revenue of $50.9 million for the second quarter of 2010.  Net income was $5.6 million or $0.31 per diluted share for the quarter. us.rd.yahoo.com |
Proposed Rules Rankle Health Insurers Regulators issued draft rules on how the companies must account for how much they spend directly on patients' medical care. online.wsj.com |
RXi Pharmaceuticals: What's Cooking? M.E. Garza submits: Shares of RXi Pharmaceuticals (NASDAQ:RXII) kept pushing higher on Tuesday, finally closing the regular trading session up at $3.21 +0.37 (13.03%) and ticking even higher during after hours trading. The stock has been picking up volume and it has continued to display very bullish behavior since we reported in September that the company is rumored to be close to a partnership deal with Pfizer (PFE). We continue to be bullish on shares of RXi Pharmaceuticals as our readers have gained well over 20% since they were alerted to the persistent rumors. Complete Story » seekingalpha.com |